Robert G. Johnson

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors

E. Lam, M. Villalona-Calero, S. Mani, 2012, Cancer Chemotherapy and Pharmacology.

Phase 1, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Intravenous Alvespimycin (KOS-1022) in Patients with Refractory Hematological Malignancies.

K. Bhalla, M. Albitar, J. Lancet, 2006 .

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

C. Hudis, L. Norton, N. Rosen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.

P. Richardson, C. Mitsiades, A. Chanan-Khan, 2005 .

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors

G. Otterson, M. Villalona-Calero, M. Hensley, 2012, Investigational New Drugs.